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SUMMARY
Aims: Resting tremor in Parkinson0s disease (PD) increases markedly during cognitive
stress. Dopamine depletion in the basal ganglia is involved in the pathophysiology of resting
tremor, but it is unclear whether this contribution is altered under cognitive stress. We test
the hypothesis that cognitive stress modulates the levodopa effect on resting tremor.
Methods: Tremulous PD patients (n = 69) were measured in two treatment conditions
(OFF vs. ON levodopa) and in two behavioral contexts (rest vs. cognitive co-activation).
Using accelerometry, we tested the effect of both interventions on tremor intensity and tre-
mor variability. Results: Levodopa significantly reduced tremor intensity (across behav-
ioral contexts), while cognitive co-activation increased it (across treatment conditions).
Crucially, the levodopa effect was significantly smaller during cognitive co-activation than
during rest. Resting tremor variability increased after levodopa and decreased during cogni-
tive co-activation. Conclusion: Cognitive stress reduces the levodopa effect on Parkinson’s
tremor. This effect may be explained by a stress-related depletion of dopamine in the basal
ganglia motor circuit, by stress-related involvement of nondopaminergic mechanisms in
tremor (e.g., noradrenaline), or both. Targeting these mechanisms may open new windows
for treatment. Clinical tremor assessments under evoked cognitive stress (e.g., counting
tasks) may avoid overestimation of treatment effects in real life.
Introduction
Tremor in Parkinson’s disease (PD) is a highly heterogeneous
and, for many patients, an agonizing symptom. It is often the
first presenting sign of PD and is ranked as the second most trou-
blesome symptom by patients in early phases of the disease [1].
Many patients complain about worsened tremor under stressful
circumstances in daily life [2]. This may create a feeling of
stigmatization and embarrassment, often leading to a vicious cir-
cle [3]. Tremor also spontaneously ‘waxes and wanes’ [4], mak-
ing it an unpredictable symptom both for patients and for
clinicians. The neural mechanisms that contribute to tremor
amplification during stress, and also to the spontaneous varia-
tions in tremor, are unclear. Having such insights would be help-
ful for the development of improved treatment strategies for
tremor. In this study, we address this issue by testing whether
the effect of levodopa on resting tremor is modulated by the
presence of acute cognitive stress.
The pathological hallmark of PD is nigrostriatal dopamine
depletion [5], but the dopaminergic basis of resting tremor is dis-
puted [6]. Specifically, striatal dopamine depletion correlates
with all motor symptoms except resting tremor [7], and
dopaminergic medication has a variable (and sometimes no)
effect on resting tremor [8,9]. This suggests that other neuro-
transmitter systems may play an (additional) role in the patho-
physiology of PD resting tremor. Accordingly, nuclear imaging
studies have shown a correlation between tremor severity and
serotonin depletion in the raphe [10,11]. Furthermore, there is
evidence for a role of the noradrenergic system in PD resting tre-
mor: Tremor-dominant PD patients have less degeneration of the
locus coeruleus (the main source of cerebral noradrenalin) than
nontremor patients [12], and intravenous injection of adrenalin
increases tremor [13]. Indeed, it has been argued that the
increase in tremor during cognitive stress could be related to acti-
vation of the locus coeruleus–noradrenergic system [14]. Taken
together, these findings suggest that different neurotransmitter
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systems may play a variable, context-specific role in the patho-
physiology of PD resting tremor.
Here, we test the hypothesis that the contribution of dopamine
depletion to PD resting tremor is modulated by acute cognitive
stress (when the noradrenergic system is activated). Using
accelerometry, we measured tremor intensity (maximal tremor
power during each condition) and tremor variability (coefficient
of variation of tremor power) at rest and during cognitive stress
(serial sevens), both OFF and ON dopaminergic medication. We
used a mental arithmetic task under social evaluation (by the
examiner), because previous studies have shown that this task
induces autonomic stress responses [15] and is associated with
activity in a cerebral stress circuit [16]. We expected a diminished
levodopa effect during cognitive stress. Furthermore, we hypothe-
sized to find higher, but more stable, tremor intensity during cog-
nitive stress.
Materials and Methods
Study Population
Patients with PD, diagnosed according to the UK Brain bank crite-
ria [17,18], were included. Patients without current dopaminergic
medications had to meet at least 3 of the “supportive UK Brain
bank criteria” (unilateral onset, rest tremor, and progressive disor-
der). We only included patients with a resting tremor score of ≥1
points (pts.) in at least one arm on item 17 of the Movement
Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS). All patients were recruited from our outpatient clinic
and examined by two independent movement disorders special-
ists. Exclusion criteria were as follows: neurological comorbidity,
signs of psychogenic tremor (e.g., entrainment or distractibility),
known allergy against levodopa–benserazide or domperidone, and
significant cognitive impairment (Mini-Mental State Examination
(MMSE) score <24 or frontal assessment battery (FAB) < 12)
[19,20].
The study was approved by the Local Ethics Committee and was
performed according to the standards of the 1964 Declaration of
Helsinki. All participants gave written informed consent prior to
their inclusion. Patients were clinically assessed using the MDS-
UPDRS-part III [21] and the Hoehn and Yahr Scale (H&Y) [22].
Design
Patients were measured twice on 1 day, both before (OFF medica-
tion) and after a levodopa challenge (ON medication). We
quantified clinical characteristics using the MDS-UPDRS and elec-
trophysiological tremor characteristics (maximal tremor intensity
and tremor variability) using accelerometry. Cognitive character-
istics were measured once, using the MMSE and the FAB.
Levodopa Challenge
All patients were evaluated after overnight fasting and in a practi-
cally defined OFF state, more than 12 h after intake of their last
dose of levodopa, more than 30 h after dopaminergic agonists,
and more than 24 h after anticholinergics or beta-blockers [23].
To avoid possible influence on tremor patients had to forgo
caffeine (tea, coffee) for >12 h. For the ON state assessment, the
patients first received 10 mg domperidone to reduce possible side
effects and to improve gastrointestinal absorption. This was fol-
lowed by a standard dose of 250 mg dispersible levodopa–benser-
azide (on average 75% higher than the patients’ own morning
dose) 1 h later [23].
Tremor Assessment
Clinical resting tremor was assessed with the MDS-UPDRS motor
scale (part III) using items 17 (tremor amplitude of the most
affected hand) and item 18 (tremor constancy, i.e., percentage of
visible rest tremor during the entire examination; range 0 to
>75%) [21]. The clinical rater was present during the entire exam-
ination and rated tremor clinically during the entire session,
including the electrophysiology part, breaks between the tasks,
and the whole MDS-UPDRS part III examination in OFF and in
ON state. Two different tremor features (of the most affected arm)
were quantified using accelerometry: tremor intensity (maximal
tremor power during each condition) and tremor variability (coef-
ficient of variation of tremor power; see section Statistical Analy-
sis). For better comparability with clinical ratings, the maximal
(rather than mean) tremor intensity was quantified with the log
values of the amplitudes, derived by accelerometry, because
MDS-UPDRS item 17 is based on the highest amplitude at any
time during the entire examination. Patients lied down comfort-
ably on a bed to achieve complete resting state. The forearms
rested in a relaxed position on two pillows, while hands and fin-
gers were unsupported. Resting tremor was recorded in two differ-
ent contexts: at rest (REST) and during cognitive co-activation
(COCO); backwards counting in steps of three or seven as fast as
possible, while the examiner verbally encouraged rapid respond-
ing (social evaluation) [24]. For each context, we collected three
trials of 60 s each.
Accelerometer Data Analysis
ECG was measured to calculate heart rate during each condition.
Resting tremor intensity was measured with a lightweight biaxial
piezoelectric accelerometer (Medifactory international; Heerlen,
the Netherlands; sensitivity: 128 Hz) attached to the dorsum of
the most affected hand. Data were stored on a computer for offline
analysis. For preprocessing, a bandpass filter of 1–40 Hz was used
to remove slow-frequency drifts and high frequencies of no inter-
est. Next, we analyzed the data using FieldTrip [25]. Specifically,
we calculated the time–frequency representations (TFR) between
1 and 20 Hz using a 2 s. Hanning taper, which resulted in a
0.5 Hz resolution. By averaging over all time points, we obtained
an average power spectrum across segments. For each patient, we
picked the TFR of the corresponding tremor frequency, resulting
in patient-specific regressors describing fluctuations in tremor
intensity during the 60-s trial. After log-transformation, we calcu-
lated maximal tremor intensity by taking the highest value of the
tremor regressor (for each patient, context, and trial). This value
reflects the highest tremor episode (based on a 2-s sliding win-
dow) during each trial. Furthermore, we calculated variability of
tremor intensity using the coefficient of variation (mean of the
tremor regressor divided by its standard deviation).
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Statistical Analysis
First, we compared the clinical characteristics (including heart
rate) OFF versus ON levodopa using paired t-tests (two-sided).
Second, we compared the electrophysiological resting tremor
characteristics (1) maximal resting tremor intensity, and (2) tre-
mor variability using two-way repeated-measures analysis of vari-
ance (ANOVA) with factors TREATMENT (OFF vs. ON levodopa)
and CONTEXT (REST vs. COCO). Third, we correlated clinical
characteristics and electrophysiological tremor characteristics, and
we correlated the dopamine response (OFF vs. ON, averaged over
REST and COCO) with the context response (COCO vs. REST,
averaged over OFF and ON), using a Spearman correlation (two-
sided). All statistical analyses were performed using SPSS (IBM
SPSS Statistics for Windows, Version 22.0, IBM Corp., Armonk,
NY, USA).
Results
A total of 71 patients (49 men; mean age: 63 years; range: 45–81)
were recruited from our outpatient clinic and examined by two
independent movement disorders specialists. The recruited
patients were moderately affected (indicated by a median HY stage
of 2), and the overall results of cognitive tests (MMSE and FAB)
indicated good cognitive functioning. Of 71 patients, two were
excluded (signs of psychogenic and atypical tremor). All analyses
were performed on the remaining 69 patients. Eight patients did
not use anti-Parkinson medication, and the others used dopamin-
ergic medication at home (levodopa and dopamine agonists; aver-
age daily levodopa equivalent: 439.5 mg; range: 0–1500 mg). Six
patients were on anticholinergics. Eight patients used beta-block-
ers (for hypertension and/or tremor). Patient characteristics are
listed in Table 1.
The first tremor assessment in ON state started on average
47 min (range: 35–59 min) after taking levodopa. Levodopa had a
significant effect on clinical measures of disease severity, including
resting tremor (Table 2). The average tremor frequency was 4.78
(0.08) Hz and was not affected by either TREATMENT or CON-
TEXT (P > 0.19). Heart rate significantly increased during COCO
(average at REST: 63  1.2 bpm, during COCO: 71  1.5 bpm;
main effect of CONTEXT, F(1,68) = 31.2; P < 0.001), but
there was no significant effect of treatment (TREATMENT,
F(1,68) = 3.2, P = 0.08), and there were no significant interac-
tions (F(1,68) = 0.4, P = 0.53). This suggests that patients experi-
enced cognitive stress during COCO.
Levodopa Effect on Tremor Intensity
Levodopa and cognitive co-activation had opposite effects on rest-
ing tremor intensity: Levodopa significantly reduced maximal tre-
mor intensity (main effect of TREATMENT, F(1,68) = 42.9;
P < 0.001), while cognitive co-activation significantly increased
tremor intensity (main effect of CONTEXT, F(1,68) = 128.9;
P < 0.001). Crucially, the effect of levodopa was significantly
smaller during COCO than during REST (TREATMENT 9 CON-
TEXT interaction, F(1,68) = 5.6; P = 0.02; Figure 1A). In other
words, the positive effect of levodopa was counteracted by a nega-
tive effect of cognitive stress such that maximal tremor intensity
during COCO in the ON state was similar to maximal tremor
intensity during REST in the OFF state (t(68) = 1.4; P = 0.2). Post
hoc t-tests revealed that the effect of levodopa was present for both
REST (t(68) = 6.9; P < 0.001) and COCO (t(68) = 4.9; P < 0.001)
conditions and that cognitive co-activation increased tremor
intensity for both OFF (t(68) = 8.7; P < 0.001) and ON
(t(68) = 10.2; P < 0.001) sessions. The effects of levodopa
(OFF > ON) and context (COCO > REST) appeared to be inde-
pendent from each other: There was no correlation between both
difference scores (Spearman’s rho = 0.12, P = 0.31).
Levodopa Effect on Tremor Variability
Levodopa significantly increased tremor variability (main effect of
TREATMENT, F(1,68) = 43.6, P < 0.001; Figure 1B), while cogni-
tive co-activation decreased tremor variability (main effect of CON-
TEXT, F(1,68) = 32.2, P < 0.001). There was no significant
interaction between the conditions (F(1,68) = 1.4, P = 0.24). This
finding indicates that patients switched more often between low-
and high-amplitude tremor in the ON state and at rest, while they
experienced a more consistent (more severe) tremor in the OFF
state and during cognitive stress.
Correlation of Clinical and Accelerometry Data
As expected, electrophysiological and clinical tremor characteristic
were strongly related. First, maximal resting tremor intensity
showed a significant and positive correlation with clinical tremor
severity (MDS-UPDRS, item 17), both OFF levodopa (REST:
q = 0.5; P < 0.001; COCO: q = 0.6; P < 0.001; see Figure 2A) and
ON levodopa (REST: q = 0.4; P < 0.001; COCO: q = 0.5;
P < 0.001). Second, maximal resting tremor intensity and the
clinical tremor constancy (item 18) were significantly correlated,
both OFF levodopa (REST: q = 0.6; P < 0.001; COCO: q = 0.5;
P < 0.001) and ON levodopa (REST: q = 0.5; P < 0.001; COCO:
q = 0.4; P < 0.01). Third, the reduction in tremor intensity, which
was clinically (item 17) and electrophysiologically detected, signif-
icantly correlated during COCO (q = 0.4; P < 0.001). Finally, we
observed a negative correlation between resting tremor variability
(using accelerometry) and tremor constancy (item 18), both in
the OFF state (REST: q = 0.5; P < 0.001; COCO: q = 0.6;
Table 1 Clinical characteristics
Age (years; mean) 63 (45–81)
Sex 20 F, 49 M
HY stage (median) 2.0 (1.0–3.0)
Disease duration (years; mean) 3.9 (0.3–15)
MMSE (mean) 29 (24–30)
FAB (mean) 17 (13–18)
Levodopa equivalent at home (mg/day; mean) 440 (0–1500)
H&Y stage, Hoehn and Yahr stage (score 0–5); MMSE, Mini-Mental State
examination (score 0–30); FAB, frontal assessment battery (score
0–18). If not indicated otherwise, data are mean (standard error of
the mean) across 69 Parkinson patients. For HY stage, higher scores
indicate worse functioning. For both FAB and MMSE, lower scores indi-
cate worse functioning. The scores were evaluated OFF medication.
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Table 2 Clinical Levodopa effect (MDS-UPDRS part III)
OFF state ON state Improvement Significance (P)
UPDRS part III OFF state (mean) 43.9 (1.80) 25.9 (1.38) 41.3% (1.79) <0.001
Tremor score MA hand (item 17; mean) 2.97 (1–4) 2.01 (0–4) 35.0% (4.12) <0.001
Tremor constancy (item 18; mean) 3.26 (1–4) 1.70 (0–4) 47.3% (4.20) <0.001
MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s disease rating scale part III (score 0–132; item 17 ranges from 0 to 20); OFF state, with-
out dopaminergic medication; ON state, after dopaminergic medication; MA hand, most affected hand. Data are mean (standard error of the mean)
across 69 Parkinson patients. Higher scores indicate worse symptoms.
Figure 1 Levodopa effect on resting tremor. Panel A shows the levodopa effect on tremor intensity (maximal tremor power during each condition,
measured with accelerometry) during REST (left) and COCO (right) in OFF and ON levodopa state (colored bars). Levodopa significantly reduced resting
tremor intensity, while COCO significantly increased it. However, the effect of levodopa was significantly smaller during COCO than REST. Panel B shows
the levodopa effect on tremor variability (coefficient of variation of tremor power) during REST and COCO. Levodopa significantly increased tremor
variability, while cognitive co-activations reduced it. Level of significance: *P < 0.05; **P < 0.01; ***P < 0.001; data are log-transformed. COCO, cognitive
co-activation.
Figure 2 Correlation of clinical versus electrophysiological evaluation. Panel A shows that increased tremor intensity (maximal tremor power, measured
using accelerometry; x-axis) was associated with increased clinical tremor severity (MDS-UPDRS item 17 for the most affected hand, range from 0 to 4
points; y-axis), during cognitive co-activation in the OFF state. Panel B shows that increased tremor variability (coefficient of variation of tremor power,
measured using accelerometry; x-axis) was associated with reduced clinical tremor constancy (MDS-UPDRS item 18; range from 0 to 4 points; y-axis)
during cognitive co-activation in the OFF state.
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P < 0.001; see Figure 2B) and in the ON state during COCO
(q = 0.6; P < 0.001).
Discussion
We tested the hypothesis that the antitremor effect of levodopa is
reduced during cognitive stress. The cognitive co-activation task
activated the noradrenergic stress system, as evidenced by a signif-
icant increase in heart rate [15]. Our main finding is that cognitive
stress reduced the ability of levodopa to suppress tremor intensity,
as compared to a resting condition. Furthermore, we found that
levodopa increased the spontaneous variability of resting tremor
amplitude, while cognitive stress decreased it.
Our findings appear to contradict a previous study by Sturman
and colleagues, who reported similar effects of levodopa on tremor
intensity for tremor at rest and for tremor during cognitive co-acti-
vation in 10 PD patients [26]. However, this discrepancy might be
explained by methodological differences: Sturman et al. only
included patients with implanted deep brain stimulation elec-
trodes in the STN, and both the patient characteristics (surgical
candidates differ from the general PD population) and micro-
lesions induced by the surgery may have altered the levodopa
response. Furthermore, while their cognitive co-activation task
was externally paced, we aimed to induce higher stress level by
instructing to “count as fast as possible” (i.e., internally paced)
[27]. Finally, our sample was considerably larger than the previ-
ous study (69 vs. 10 patients).
Possible Mechanisms Underlying the Reduced
Levodopa Effect on Tremor During Cognitive
Stress
The finding that levodopa had a relatively reduced antitremor
effect during cognitive stress may be explained by the involve-
ment of nondopaminergic mechanisms, or by a depletion of avail-
able dopamine during cognitive stress, or both. Our task reliably
activated the noradrenergic stress system, as evidenced by a signif-
icant increase in heart rate [15,27]. Although it is known that the
noradrenergic system is affected in early stage PD [28], neu-
ropathological studies revealed a high association of locus coeru-
leus degeneration with akinetic-rigid phenotypes, but only
minimal involvement of the locus coeruleus in tremor-dominant
patients [12,14]. This suggests that an intact noradrenergic system
may be necessary for the development of tremor, although there
is no evidence for a causal link. Animal studies have shown that
an acute stressor produces motor hyperactivity, possibly mediated
through direct effects of noradrenalin onto the cerebral motor cir-
cuit [29]. Using fMRI, we have previously shown that PD resting
tremor is triggered by the dopamine-depleted basal ganglia, and
amplified in the cerebello-thalamo-cortical circuit [30]. The locus
coeruleus sends noradrenergic projections to all nodes of the cere-
bello-thalamo-cortical circuit [14,27], which may amplify tremu-
lous activity in this circuit.
Another possibility is that cognitive stress depleted available
dopamine in tremor-related regions of the basal ganglia and that
our dopaminergic intervention was insufficient to replete this
functional deficit. More specifically, it is conceivable that our (cog-
nitive) task leads to a redistribution of dopamine from motor to
cognitive portions of the cortico-striatal circuit, causing dopamine
depletion in the cortico-striatal motor loop. On the other
hand, our dopaminergic intervention (levodopa/benserazide
200/50 mg) was considerably larger than the dose taken by most
patients. This makes underdosing unlikely—even in the presence
of cognitive co-activation. Neuroimaging studies may further test
whether cognitive stress increases PD tremor by activating the
noradrenergic system, by depleting the dopaminergic system, or
both.
Finally, it is also unlikely that our task increased tremor through
the peripheral nervous system, given the immediate effect of cog-
nitive stress on tremor intensity (i.e., in less than a second). Fur-
thermore, previous work has shown that adrenalin administration
only increases Parkinson’s tremor when injected intravenously
(i.e., systemically, enabling central effects [31]), but not when
injected into an artery—which distributes adrenalin to the muscle
[32]. It is also unlikely that psychological stress modulates tremor
through spinal mechanisms, given absent effects of cognitive
stress on the Hoffmann’s reflex [33,34].
Tremor Variability
Tremor variability was highest during the ON-REST state and low-
est during the OFF-COCO state. A possible explanation for the
high variability ON levodopa is that levodopa desynchronizes
oscillatory activity in the basal ganglia, leading to more irregular
tremor frequencies [26]. Since frequency changes are associated
with (temporary) amplitude reductions, this may have lead to
higher amplitude variability in ON state [35]. High tremor vari-
ability may continuously bring this symptom under the patient’s
attention, thereby contributing to a subjective experience of many
patients that levodopa is ineffective in reducing resting tremor,
whereas in fact the tremor amplitude is lower.
Clinical Implications
The decreased levodopa effect during cognitive stress underlines
the importance of using simple (rapid) counting tasks for clinically
assessing tremor [24]. Although there are several tremor provoca-
tion tasks, the serial-sevens task used here is one of the most prac-
ticable ones [24]. Otherwise, it is possible that the clinical
examination underestimates tremor intensity and, importantly,
potentially overestimates the effect of levodopa and therefore does
not reflect the patient’s tremor burden in daily life. Ideally, tre-
mor-rating scales should describe explicitly under which circum-
stances the tremor was scored, because the context obviously has
a major effect on tremor severity. Currently, the resting tremor
rating in MDS-UPDRS part III (item 17) only scores the maximal
tremor amplitude in the context chosen by the investigator.
Our findings highlight an important clinical problem: Patients
suffer most from tremor in stressful circumstances, when available
(dopaminergic) therapy is least effective. This calls for new treat-
ments aimed at reducing the influence of acute stress on resting
tremor. This may be achieved by cognitive behavioral therapy
[36] or pharmacological therapy that blocks noradrenergic trans-
mission (e.g., beta-blockers).
Our findings may also have implications for future studies
aimed at enhancing noradrenergic activity in PD. Specifically, it has
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been suggested that noradrenergic enhancement may alleviate
symptoms such as apathy, cognitive dysfunction, freezing of gait,
and sleep disorders [37]. Our findings raise the possibility that
noradrenergic enhancement is not suitable for a subset of patients
that are particularly sensitive to the effects of acute cognitive stress
on resting tremor.
Interpretational Issues
We did not collect a direct measure of activity in the locus
coeruleus–noradrenergic system. Thus, although our task was
associated with increased heart rate, which is associated with
noradrenergic activity [15], we cannot rule out an additional
effect of distraction, concentration, or speaking—as in previous
studies [38]. Also, our findings do not suggest that noradrenergic
activity is the only factor that modulates tremor intensity: Motor
co-activation (such as walking or finger tapping with the hand
contralateral to the tremor) can also increase tremor, possibly
through other mechanisms [24].
We only measured electrophysiological tremor severity (with
accelerometry) on the most affected arm. Therefore, it remains
unclear whether our findings can be extrapolated to tremor in
other body parts—although it is unlikely that tremors in different
body parts have a different pathophysiology.
All patients were aware of the intervention, and therefore, a pla-
cebo effect may have contributed to the tremor reduction in the ON
state. However, an influence on our main finding (interaction effect
with context) is unlikely, since a placebo effect would have been
similar for both contexts. For the same reason, it is unlikely that our
findings are influenced by order effects (ON was always after OFF).
Finally, given the absence of validated context-specific tremor-
rating scales, we do not have clinical ratings separately for the
REST and COCO conditions [39]. This makes it difficult to judge
the clinical relevance of our accelerometry findings.
Conclusion
Our results show a reduced levodopa effect in PD resting tremor
during cognitive stress and lower tremor variability in this con-
text. Both findings have clinical relevance: They emphasize the
impact of simple counting tasks in clinical practice to avoid overes-
timation of treatment effects visible at rest. Mechanistically, our
findings suggest that not only dopaminergic, but also non-
dopaminergic, circuits may be involved in the pathophysiology of
Parkinson’s tremor—and that the contribution of different circuits
may be context-specific. Finally, our findings open new windows
for personalized treatment of Parkinson’s tremor, taking patient-
and context-specific factors into account.
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